{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:53:01Z","timestamp":1792155181475,"version":"4.4.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003803","name":"University of Hong Kong","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003803","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s40265-022-01751-x","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T10:03:20Z","timestamp":1660298600000},"page":"1193-1205","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries"],"prefix":"10.1007","volume":"82","author":[{"given":"Swathi","family":"Pathadka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent K. C.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin Fen","family":"Neoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoud","family":"Al-Badriyeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C. M.","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica A.","family":"Slavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Cowling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan F. N.","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian C. K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7602-9470","authenticated-orcid":false,"given":"Esther W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"1751_CR1","doi-asserted-by":"publisher","first-page":"17120","DOI":"10.1038\/nmicrobiol.2017.120","volume":"2","author":"Stop neglecting fungi","year":"2017","unstructured":"Stop neglecting fungi. Nat Microbiol. 2017;2:17120.","journal-title":"Nat Microbiol"},{"key":"1751_CR2","unstructured":"Global Action Fund for Fungal Infections. 95\u201395 by 2025. Improving outcomes for patients with fungal infections across the world: a roadmap for the next decade. 2020. https:\/\/www.gaffi.org\/. Accessed 19 Feb 2020."},{"issue":"12","key":"1751_CR3","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/jac\/dkw325","volume":"71","author":"M Kneale","year":"2016","unstructured":"Kneale M, Bartholomew JS, Davies E, Denning DW. Global access to antifungal therapy and its variable cost. J Antimicrob Chemother. 2016;71(12):3599\u2013606.","journal-title":"J Antimicrob Chemother"},{"key":"1751_CR4","unstructured":"World Health Organization. WHO model list of essential medicine, 21st list. 2019. https:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/en\/. Accessed 17 Aug 2020."},{"issue":"1","key":"1751_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1473-3099(18)30547-4","volume":"19","author":"Y Hsia","year":"2019","unstructured":"Hsia Y, Sharland M, Jackson C, Wong ICK, Magrini N, Bielicki JA. Consumption of oral antibiotic formulations for young children according to the WHO Access, Watch, Reserve (AWaRe) antibiotic groups: an analysis of sales data from 70 middle-income and high-income countries. Lancet Infect Dis. 2019;19(1):67\u201375.","journal-title":"Lancet Infect Dis"},{"key":"1751_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjgh-2018-001241","volume":"4","author":"C Jackson","year":"2019","unstructured":"Jackson C, Hsia Y, Bielicki JA, et al. Estimating global trends in total and childhood antibiotic consumption, 2011\u20132015. BMJ Glob Health. 2019;4:1.","journal-title":"BMJ Glob Health"},{"issue":"12","key":"1751_CR7","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1136\/adc.2004.050468","volume":"89","author":"ICK Wong","year":"2004","unstructured":"Wong ICK, Murray ML, Camilleri-Novak D, Stephens P. Increased prescribing trends of paediatric psychotropic medications. Arch Dis Child. 2004;89(12):1131.","journal-title":"Arch Dis Child"},{"key":"1751_CR8","unstructured":"World Bank. World Bank Country and Lending Groups. 2020. https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups. Accessed 7 Aug 2020."},{"key":"1751_CR9","unstructured":"United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects 2019. 2020. https:\/\/population.un.org\/wpp\/. Accessed 14 Jul 2020."},{"key":"1751_CR10","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. Use of ATC\/DDD: DDD indicators. 2020. https:\/\/www.whocc.no\/use_of_atc_ddd\/#indica. Accessed 9 Aug 2020."},{"issue":"8","key":"1751_CR11","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/S1473-3099(14)70780-7","volume":"14","author":"TP Van Boeckel","year":"2014","unstructured":"Van Boeckel TP, Gandra S, Ashok A, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014;14(8):742\u201350.","journal-title":"Lancet Infect Dis"},{"key":"1751_CR12","unstructured":"European Centre for Disease Prevention and Control. Antimicrobial consumption\u2014Annual Epidemiological Report for 2018. 2020. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/surveillance-antimicrobial-consumption-europe-2018. Accessed 6 Mar 2020."},{"issue":"165","key":"1751_CR13","doi-asserted-by":"publisher","first-page":"165rv13","DOI":"10.1126\/scitranslmed.3004404","volume":"4","author":"GD Brown","year":"2012","unstructured":"Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med. 2012;4(165):165rv13.","journal-title":"Sci Transl Med"},{"key":"1751_CR14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/jof3010003","volume":"3","author":"H Kaur","year":"2017","unstructured":"Kaur H, Chakrabarti A. Strategies to reduce mortality in adult and neonatal candidemia in developing countries. J Fungi (Basel). 2017;3:3.","journal-title":"J Fungi (Basel)"},{"key":"1751_CR15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/jof3010004","volume":"3","author":"F Bongomin","year":"2017","unstructured":"Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi (Basel). 2017;3:4.","journal-title":"J Fungi (Basel)"},{"key":"1751_CR16","doi-asserted-by":"crossref","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392(10159):1789\u2013858.","DOI":"10.1016\/S0140-6736(18)32279-7"},{"issue":"11","key":"1751_CR17","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1016\/S1473-3099(18)30103-8","volume":"18","author":"DW Denning","year":"2018","unstructured":"Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis. 2018;18(11):e339\u201347.","journal-title":"Lancet Infect Dis"},{"key":"1751_CR18","doi-asserted-by":"publisher","first-page":"18026","DOI":"10.1038\/nrdp.2018.26","volume":"4","author":"PG Pappas","year":"2018","unstructured":"Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Rev Dis Primers. 2018;4:18026.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"1751_CR19","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","volume":"62","author":"PG Pappas","year":"2016","unstructured":"Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-50.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1751_CR20","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/jac\/dkx444","volume":"73","author":"F Lamoth","year":"2018","unstructured":"Lamoth F, Lockhart SR, Berkow EL, Calandra T. Changes in the epidemiological landscape of invasive candidiasis. J Antimicrob Chemother. 2018;73(1):i4\u201313.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 6","key":"1751_CR21","doi-asserted-by":"publisher","first-page":"S612","DOI":"10.1093\/cid\/civ791","volume":"61","author":"DS Perlin","year":"2015","unstructured":"Perlin DS. Echinocandin resistance in candida. Clin Infect Dis. 2015;61(Suppl 6):S612\u20137.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1751_CR22","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ijantimicag.2017.05.019","volume":"50","author":"D Farmakiotis","year":"2017","unstructured":"Farmakiotis D, Kontoyiannis DP. Epidemiology of antifungal resistance in human pathogenic yeasts: current viewpoint and practical recommendations for management. Int J Antimicrob Agents. 2017;50(3):318\u201324.","journal-title":"Int J Antimicrob Agents"},{"key":"1751_CR23","doi-asserted-by":"crossref","unstructured":"Munoz P, Bouza E, Group Cs. The current treatment landscape: the need for antifungal stewardship programmes. J Antimicrob Chemother 2016;71(suppl 2):ii5\u2013ii12.","DOI":"10.1093\/jac\/dkw391"},{"issue":"1","key":"1751_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s40121-020-00382-7","volume":"10","author":"FB Cavassin","year":"2021","unstructured":"Cavassin FB, Ba\u00fa-Carneiro JL, Vilas-Boas RR, Queiroz-Telles F. Sixty years of amphotericin B: an overview of the main antifungal agent used to treat invasive fungal infections. Infect Dis Therapy. 2021;10(1):115\u201347.","journal-title":"Infect Dis Therapy"},{"key":"1751_CR25","unstructured":"Global Action Fund for Fungal Infections. Gilead reduces price of AmBisome (liposomal amphotericin B) for cryptococcal meningitis in HIV\/AIDS. 2022. https:\/\/gaffi.org\/gilead-reduces-price-of-ambisome-liposomal-amphotericin-b-for-cryptococcal-meningitis-in-hiv-aids\/. Accessed 1 Jul 2022."},{"issue":"7","key":"1751_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1473-3099(13)70078-1","volume":"13","author":"A Loyse","year":"2013","unstructured":"Loyse A, Thangaraj H, Easterbrook P, et al. Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet Infect Dis. 2013;13(7):629\u201337.","journal-title":"Lancet Infect Dis"},{"key":"1751_CR27","unstructured":"U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. 2020. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-limits-usage-nizoral-ketoconazole-oral-tablets-due-potentially. Accessed 12 Mar 2020."},{"key":"1751_CR28","unstructured":"European Medicines Agency. Ketoconazole-containing medicines. 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/ketoconazole-containing-medicines. Accessed 20 Apr 2020."},{"key":"1751_CR29","unstructured":"U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA warns that prescribing of Nizoral (ketoconazole) oral tablets for unapproved uses including skin and nail infections continues; linked to patient death. 2020. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-warns-prescribing-nizoral-ketoconazole-oral-tablets-unapproved. Accessed 27 Mar 2020."},{"issue":"2","key":"1751_CR30","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/pbc.25273","volume":"62","author":"J Kirby","year":"2015","unstructured":"Kirby J, Ojha RP, Johnson KM, Bittner EC, Caniza MA. Challenges in managing infections among pediatric cancer patients: Suboptimal national essential medicines lists for low and middle income countries. Pediatr Blood Cancer. 2015;62(2):204\u20137.","journal-title":"Pediatr Blood Cancer"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01751-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01751-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01751-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T13:39:42Z","timestamp":1669901982000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-022-01751-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1751"],"URL":"https:\/\/doi.org\/10.1007\/s40265-022-01751-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"5 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported through internal seed funding from the Li Ka Shing Faculty of Medicine, The University of Hong Kong. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"EWC has received research grants from the Research Grants Council (RGC, Hong Kong), Narcotics Division of the Security Bureau of the Government of the Hong Kong SAR, Research Fund Secretariat of the Food and Health Bureau, National Natural Science Fund of China, Wellcome Trust, Bayer, Bristol-Myers Squibb, Pfizer, Janssen, Amgen, and Takeda, outside the submitted work. ICKW has received research grants from Research Grants Council (RGC, Hong Kong), Innovative Medicines Initiative (IMI), Shire, Janssen-Cilag, Eli-Lily, Pfizer, Bayer, and grants from European Union FP7 program, outside the submitted work. DCMK has sat on advisory boards for Becton Dickinson Pty Ltd and Merck Sharp & Dohme (MSD), and received financial support from MSD and F2G, outside the submitted work. MS has received grants from Gilead Sciences, Merck, F2G, and Pfizer unrelated to the submitted work. BJC has received funding from Sanofi Pasteur and Roche, outside the submitted work. The other author(s) declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"EWC, SP, and VKCY conceptualized the study. EWC provided resources, acquired the data and supervised this study. SP and VKCY conducted analysis and formulated the original draft. All authors reviewed the manuscript critically and commented on manuscript drafts.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}